Conferences & events
Come & meet our amazing team
Genoskin at the SOT 65th Annual Meeting & ToxExpo
Driving innovation in non-clinical toxicity assessment with ex vivo human skin and mast cell models
We are pleased to announce that Genoskin will return to the SOT Annual Meeting and ToxExpo, taking place March 22–25, 2026, at the San Diego Convention Center in San Diego, California. Recognized as one of the premier global events in toxicology, the SOT Annual Meeting brings together leading scientists from academia, industry, and regulatory agencies to explore cutting-edge advances in toxicological research.
At this year’s meeting, Genoskin will present three scientific posters highlighting how our ex vivo human skin platforms generate highly relevant human data to support immunotoxicity and local tolerance assessments at the injection site.
Our poster presentations at SOT 2026
1. Recreating scalp inflammation ex vivo: A human hair follicle–preserving model for immunotoxicological and therapeutic assessment
Abstract #3372 | Poster Board G515, Hall B
Session Date & Time: Monday, March 23 | 1:45 PM – 4:15 PM
We present a bio-stabilized ex vivo human scalp model that reproduces bacterial-like inflammation via topical LPS exposure. The platform preserves tissue and hair follicle architecture while triggering measurable cytokine release (e.g., GM-CSF, IL-8, MIP-1β) and modulating follicle turnover through reduced proliferation and increased apoptosis—supporting physiologically relevant testing of anti-inflammatory scalp therapies.
2. Hyposkin® as translational tool for local toxicity screening: early-stage formulation safety assessment
Abstract #3267 | Poster Board E399, Hall B
Session Date & Time: Monday, March 23 | 9:15 AM – 11:45 AM
Formulation safety testing still relies heavily on in vivo studies due to limited validated in vitro alternatives. Genoskin’s HypoSkin® biostabilized ex vivo human skin enables multi-parametric local tolerance assessment after subcutaneous injection. In a validation study, the model detected toxic control formulations with strong in vitro–in vivo correlation, using robust macroscopic imaging and histopathology endpoints for standardized scoring.
3. Replacing animal testing in local tolerance assessment of an injection device: Human ex vivo HypoSkin® model as a New Approach Methodology (NAM)
Abstract #4169 | Poster Board J652, Hall B
Session Date & Time: Tuesday, March 24 | 1:45 PM – 4:15 PM
HypoSkin® is an ex vivo human skin NAM that preserves native immune cells and tissue architecture for local tolerance testing. Using a customized workflow, we compared an innovative fixed-depth intradermal device with a 30G syringe and reference device. All injections were well tolerated, with preserved histology and only mild, physiological cytokine responses, including comparable vaccine-induced activation.
Advancing toxicology: Ethical and predictive human-relevant models
The global regulatory shift towards New Approach Methodologies (NAMs) is driving the need to reduce reliance on animal testing. In response, our human-based platforms—including HypoSkin®, HairSkin®, and human primary mast cells—offer ethical and highly predictive solutions for assessing immunotoxicity at the injection site.
Our cutting-edge ex vivo models effectively bridge the gap between early non-clinical studies and clinical human outcomes, providing robust alternatives for toxicology research across pharmaceuticals, biologics, and chemical formulations.
Join our experts at SOT 2026
Genoskin booth #1051
Don’t miss the opportunity to connect with our team of experts at SOT 2026 in San Diego, California! We invite attendees to visit our poster presentations and learn how our ex vivo human skin and mast cell platforms can enhance your research on toxicity.
We look forward to a memorable time of scientific exchange and collaboration! Stay tuned for more updates.
Comments are closed.
